inhibitor

(redirected from protease inhibitor)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia, Wikipedia.
Related to protease inhibitor: fusion inhibitor, Serine protease inhibitor
See: deterrent
References in periodicals archive ?
Among people in whom Prezista failed, lower proportions lost sensitivity to protease inhibitors (PIs) or nucleoside reverse transcriptase inhibitors (NRTIs) they were taking when compared with people in whom Kaletra failed.
The results from studies with protease inhibitors were met with so much enthusiasm that many researchers were discussing the possibility of eradicating the virus from a person's body.
Protease inhibitor combination therapy represents one major advance in the clinical management of HIV infection.
On the other hand, HIV resistant to one protease inhibitor may not be resistant to all other protease inhibitors.
HCV protease inhibitors represent a promising class of drugs for HCV, and the HCV NS3/4 protease is an attractive drug target because of its involvement in viral replication and suppressive effects on host response to viral invasion.
Boehringer Ingelheim is committed to the rapid development of the investigational non-peptidic protease inhibitor (NPPI) tipranavir in phase III clinical trials and recently acquired the nucleoside analogue (NRTI) MIV-310 currently in phase II development.
Through this partnership with Vertex, a leader in the discovery and development of HCV protease inhibitors, we hope to accelerate the advancement of novel therapeutics for hepatitis C infection, and we are pleased to add VX-950 to our pipeline of innovative drugs in development.
Patient has shown substantial drug resistance, has had poor protease inhibitor exposure, and may not be adherent.
The rates of prematurity ranged from a low of 12% among those who took zidovudine plus lamivudine to a high of 24% among those who took combination therapy that did not contain a protease inhibitor.
The four marketed protease inhibitor drugs are vastly improving the condition of many people with the human immunodeficiency virus, which causes AIDS.
Parts two to five present various case studies of successful protease inhibitor drug design and development, as well as current and potential uses of such inhibitors in pharmaceutical medicine, covering the major therapeutic targets HIV-1 protease, renin, beta-secretase, gamma-secretase,plasmepsins and fungal proteases.
Successful established protease inhibitor drugs on the market -- ACE inhibitors and HIV protease inhibitors -- act by inhibiting key proteases.